30.03.2021 08:00:22

Novartis Gets Rights To Develop Therapeutic Applications For Library Of FAP Assets

(RTTNews) - Novartis (NVS) has obtained worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, Inc. The deal also includes co-exclusive rights for Novartis to develop imaging applications for these assets.

Susanne Schaffert, President, Novartis Oncology, said: "FAP is an exciting target and these agents are a great fit with our radioligand therapy pipeline, which we are actively investigating across multiple tumor types. We believe this technology has the potential to transform many patients' lives."

Analysen zu Novartis AG (Spons. ADRS)mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Novartis AG (Spons. ADRS) 101,50 -0,49% Novartis AG (Spons. ADRS)